ArticleACS chemical biology2018
NCI Program for Natural Product Discovery: A Publicly-Accessible Library of Natural Product Fractions for High-Throughput Screening.
Article in ACS chemical biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 153 citations in OpenAlex.
- Identification and characterization of five anti-mitotic sesquiterpene lactones fromPharmaceutical biology · 2026Article
- Positive selection screen identifies natural product β-catenin inactivators.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Developing a Fluorescence-Based High-Throughput Screening Method for Natural Product Fractions to Identify Inhibitors of AR-V7 for Castration-Resistant Prostate Cancer.Pharmaceutics · 2026Article
- Cytotoxic Microspinosamides from the Marine SpongeMarine drugs · 2026Article
- Homo-/Heterodimeric Substrates Bias the Type and Multiplicity of Hydroxamic Acid Chelators Assembled by a NIS Synthetase DesD.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Machine learning-assisted identification and validation of NRP1 inhibitors through molecular docking and dynamics simulations.Scientific reports · 2026Article
- A Pyrone Glucoside fromBiomolecules · 2026Article
- Semisynthesis of Mycothiazole Analogs having Distinct Bioactivity.ACS medicinal chemistry letters · 2026Article
- Structural determination of natural products at speeds and scale of high-throughput screening.Natural product reports · 2026Review
- Vosamidines A-C, Polycyclic 2-Aminoimidazole Alkaloids from a Marine Calcareous SpongeOrganic letters · 2026Article
- Geodiamolide A, a Marine Sponge Depsipeptide, Halts Proliferation and Triggers Cell Death in Squamous Cell Carcinoma (A431, NMSC) In Vitro.International journal of molecular sciences · 2026Article
- Utilizing the HiBiT System to Identify CARM1 Degraders for Targeted Cancer Therapy.Journal of medicinal chemistry · 2026Article
- Exploring the chemodiversity of antimicrobial minalemines from Didemnum granulatum by neutral loss graph.Scientific reports · 2026Article
- High-throughput screening for biostimulant discovery: opportunities to enhance nitrogen use efficiency.Frontiers in plant science · 2026Review
- Anticancer natural products from the Middle East and North Africa: biodiversity, mechanisms, and translational challenges.Frontiers in oncology · 2026Review
- Computational Strategies for Discovering Inhibitors Targeting Therapeutic Enzymes.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Antiproliferative Effects of Polar Extracts of the Aerial Parts ofPlants (Basel, Switzerland) · 2025Article
- Discovery, biosynthesis, and bioactivities of peptidic natural products from marine sponges and sponge-associated bacteria.Natural product reports · 2025Review
- Chemodiversity of Cyanobacteria from Brazil Investigated by Metabolomics and Bioassays.ACS omega · 2025Article
- High-Seas Marine Microorganism Delivers an Extract That Dampens LPS-Driven Pro-Inflammatory Signaling:Marine drugs · 2025Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
Abstract
The US National Cancer Institute's (NCI) Natural Product Repository is one of the world's largest, most diverse collections of natural products containing over 230,000 unique extracts derived from plant, marine, and microbial organisms that have been collected from biodiverse regions throughout the world. Importantly, this national resource is available to the research community for the screening of extracts and the isolation of bioactive natural products. However, despite the success of natural products in drug discovery, compatibility issues that make extracts challenging for liquid handling systems, extended timelines that complicate natural product-based drug discovery efforts and the presence of pan-assay interfering compounds have reduced enthusiasm for the high-throughput screening (HTS) of crude natural product extract libraries in targeted assay systems. To address these limitations, the NCI Program for Natural Product Discovery (NPNPD), a newly launched, national program to advance natural product discovery technologies and facilitate the discovery of structurally defined, validated lead molecules ready for translation will create a prefractionated library from over 125,000 natural product extracts with the aim of producing a publicly-accessible, HTS-amenable library of >1,000,000 fractions. This library, representing perhaps the largest accumulation of natural-product based fractions in the world, will be made available free of charge in 384-well plates for screening against all disease states in an effort to reinvigorate natural product-based drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.